Gold prices bounce off 3-week lows; demand likely longer term
Pulmatrix (NASDAQ:PULM), Inc., a pharmaceutical company specializing in the development of inhaled therapies, has announced the scheduling of its 2024 Annual Meeting of Stockholders for December 18, 2024. The record date for stockholders entitled to vote at the meeting is set for the close of business on October 31, 2024.
This announcement, filed with the SEC on Tuesday, marks a change from the 2023 Annual Meeting's anniversary date by more than 30 days. Consequently, the company has issued deadlines for stockholder proposals and nominations for directorship, which must be received by October 18, 2024.
Stockholders wishing to submit proposals for inclusion in the proxy materials, as per Rule 14a-8 of the Securities Exchange Act of 1934, must meet the SEC's requirements and send their proposals to the Corporate Secretary by the stated deadline. Similarly, those intending to present business or nominate directors outside of Rule 14a-8 must send their written notice, including all necessary information as specified in the company's Bylaws, to the Chief Executive Officer by the same date.
Additionally, in accordance with the universal proxy rules, any stockholder aiming to solicit proxies in support of their own director nominees must provide the required notice under Rule 14a-19 by October 18, 2024.
The definitive proxy statement, which will include the time and location of the 2024 Annual Meeting, will be filed with the SEC at a later date.
InvestingPro Insights
As Pulmatrix, Inc. prepares for its 2024 Annual Meeting of Stockholders, investors may benefit from additional financial insights. According to InvestingPro data, Pulmatrix has a market capitalization of $7.6 million USD, reflecting its current market valuation. The company's revenue for the last twelve months as of Q2 2024 stands at $11.39 million USD, with a significant revenue growth of 64.55% over the same period.
InvestingPro Tips highlight that Pulmatrix holds more cash than debt on its balance sheet, which could be a positive sign for investors concerned about the company's financial stability. However, it's also noted that the company is quickly burning through cash and is not profitable over the last twelve months. These factors may be important considerations for stockholders as they prepare for the upcoming annual meeting.
For those seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide valuable context for Pulmatrix's financial situation and market performance. These insights could be particularly relevant as shareholders consider proposals and director nominations for the 2024 Annual Meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.